Glow – TB-500 10mg / BPC-157 10mg / GHK-Cu 50mg

GLOW 70 mg is a high-purity multi-peptide research preparation containing GHK-Cu, BPC-157 and Thymosin Beta 4 (TB-500), supplied exclusively for scientific investigation and controlled laboratory experimentation. For research use only — not for human or veterinary use.  

Product Overview

GLOW 70 mg is a multi-peptide research preparation combining three independently characterised peptide components within a single lyophilized research vial. The formulation contains 50 mg GHK-Cu, 10 mg BPC-157 and 10 mg Thymosin Beta 4 (TB-500), providing a total nominal peptide content of 70 mg. Each component represents a distinct area of experimental peptide research. GHK-Cu is a copper-binding tripeptide investigated within peptide chemistry and molecular signalling research. BPC-157 is studied in experimental peptide and cellular signalling models, while Thymosin Beta 4 is examined within controlled cellular and peptide biology research. Independent third-party laboratory analysis of this production batch measured assay contents of 49.6 mg GHK-Cu, 8.96 mg BPC-157 and 10.95 mg Thymosin Beta 4 (TB-500). Chromatographic analysis confirmed greater than 99.8 percent purity for all three independently analysed peptide components. Identity was independently evaluated through spectrum analysis, retention time analysis and mass spectrometry. Molecular ion masses were identified at 340 Da for GHK-Cu, 1418 Da for BPC-157 and 4963 Da for TB-500. Microbiological testing reported 0 CFU/g for both total aerobic microbial count and total yeast and mold count, while bacterial endotoxin analysis returned a result below 0.001 EU/mg. Comprehensive elemental impurity screening additionally reported arsenic, cadmium, mercury, lead, nickel, vanadium and cobalt below 0.001 ppm. With all three peptide components independently characterised, GLOW 70 mg provides researchers with extensive batch-specific analytical documentation suitable for advanced multi-peptide investigations and controlled in vitro laboratory studies.  

Peptide Overview

GLOW 70 mg combines three structurally distinct research peptides: GHK-Cu, BPC-157 and Thymosin Beta 4 (TB-500). GHK-Cu is a copper-binding tripeptide consisting of glycyl-L-histidyl-L-lysine associated with copper and is commonly investigated within peptide chemistry, molecular signalling and cellular research models. BPC-157 is a synthetic peptide research compound utilised in experimental investigations involving peptide-mediated molecular interactions and cellular signalling systems. Thymosin Beta 4 is a peptide research compound investigated within experimental cellular biology, peptide interactions and molecular signalling research. Combining these three components within a single research preparation provides investigators with a multi-component material for controlled comparative and combined peptide research. Each component was independently evaluated by Liquilabs for assay content, purity and identity, providing transparent analytical documentation for the complete GLOW 70 mg research preparation.  

Historical Background and Scientific Context

Advances in peptide synthesis and analytical chemistry have enabled researchers to develop increasingly sophisticated multi-component peptide preparations for controlled scientific investigation. Modern analytical technologies make it possible to characterise individual compounds within combined peptide preparations rather than evaluating only the formulation as a whole. Chromatographic techniques can independently determine assay content, purity and retention time characteristics for individual peptide components, while mass spectrometry provides additional molecular identity verification. Microbiological analysis, bacterial endotoxin testing and elemental impurity screening further contribute to comprehensive batch-specific analytical characterisation. GLOW 70 mg represents a multi-peptide research preparation in which GHK-Cu, BPC-157 and Thymosin Beta 4 have each been independently evaluated within the same production batch.  

Mechanistic Focus in Research

Within controlled laboratory environments, the individual components of GLOW may be investigated in relation to peptide chemistry, molecular signalling and cellular communication systems. Research investigations frequently explore:

• Multi-peptide interaction research
• Copper-peptide complex investigations
• Peptide-mediated cellular signalling
• Intracellular molecular communication
• Cellular regulatory mechanisms
• Biochemical pathway analysis
• Molecular peptide interactions
• Comparative peptide investigations
• Controlled in vitro multi-peptide studies

These experimental models allow researchers to investigate multiple peptide-related molecular systems while maintaining carefully controlled laboratory conditions.  

Analytical Verification (COA)

Each batch of GLOW supplied by Grail Formula undergoes comprehensive independent third-party laboratory verification to characterise the individual peptide components and important laboratory quality parameters. Analytical testing for this batch was performed by Liquilabs s.r.o. Czechia using chromatographic, spectrometric, microbiological and mass spectrometry techniques. Batch: GF-GLOW70-B242

• GHK-Cu Content: 50 mg
• GHK-Cu Assay Content: 49.6 mg
• GHK-Cu Purity: greater than 99.8 %
• GHK-Cu Identification by Spectrum: 340
• GHK-Cu Identification by Retention Time: 0.991
• GHK-Cu Molecular Ion Mass: 340 Da
• BPC-157 Content: 10 mg
• BPC-157 Assay Content: 8.96 mg
• BPC-157 Purity: greater than 99.8 %
• BPC-157 Identification by Spectrum: greater than 1000
• BPC-157 Identification by Retention Time: 0.983
• BPC-157 Molecular Ion Mass: 1418 Da
• Thymosin Beta 4 (TB-500) Content: 10 mg
• Thymosin Beta 4 (TB-500) Assay Content: 10.95 mg
• Thymosin Beta 4 (TB-500) Purity: greater than 99.8 %
• Thymosin Beta 4 (TB-500) Identification by Spectrum: 984
• Thymosin Beta 4 (TB-500) Identification by Retention Time: 0.987
• Thymosin Beta 4 (TB-500) Molecular Ion Mass: 4963 Da
• Bacterial Endotoxins: below 0.001 EU/mg
• Total Aerobic Microbial Count: 0 CFU/g
• Total Yeast and Mold Count: 0 CFU/g

Independent peptide screening measured assay contents of 49.6 mg for GHK-Cu, 8.96 mg for BPC-157 and 10.95 mg for Thymosin Beta 4 (TB-500). Purity analysis confirmed greater than 99.8 percent purity for each of the three independently analysed peptide components. Retention time analysis returned 0.991 for GHK-Cu, 0.983 for BPC-157 and 0.987 for Thymosin Beta 4 (TB-500). Mass spectrometry identified molecular ion masses of 340 Da for GHK-Cu, 1418 Da for BPC-157 and 4963 Da for TB-500. Bacterial endotoxin testing returned a result below 0.001 EU/mg, remaining within the laboratory’s stated acceptable range of 0–0.5 EU/mg. Microbiological testing reported 0 CFU/g for total aerobic microbial count and 0 CFU/g for total yeast and mold count. Independent elemental impurity analysis reported arsenic, cadmium, mercury, lead, nickel, vanadium and cobalt below 0.001 ppm. These analytical procedures provide extensive independent batch-specific characterisation of all three peptide components together with microbiological, endotoxin and elemental impurity testing.  

Research Applications

Within controlled laboratory environments, GLOW 70 mg may be utilised in experimental models designed to investigate multi-peptide biology, molecular signalling and biochemical interactions. Examples of research applications include:

• Multi-peptide interaction investigations
• GHK-Cu peptide-complex research
• BPC-157 peptide investigations
• Thymosin Beta 4 peptide research
• Peptide-mediated signalling studies
• Cellular communication research
• Molecular pathway analysis
• Comparative peptide investigations
• Controlled in vitro multi-peptide studies

These applications are intended exclusively for scientific and laboratory investigation.  

Grail Formula Quality

Every Grail Formula research compound is supported by comprehensive independent analytical verification and transparent batch-specific laboratory documentation. For this GLOW 70 mg production batch, independent laboratory testing included:

• Individual assay determination for all three peptide components
• Individual purity assessment for all three peptide components
• Spectrum-based identity analysis
• Retention time identity verification
• Molecular ion mass identification
• Bacterial endotoxin analysis
• Total aerobic microbial count
• Total yeast and mold count
• Comprehensive elemental impurity screening
• Complete batch-specific traceability

Independent analysis of each peptide component provides researchers with detailed analytical information relating directly to the tested production batch rather than relying solely on the nominal formulation. This approach supports analytical transparency, batch traceability and consistency across Grail Formula research compounds.  

When You Choose Grail Formula

When selecting Grail Formula, researchers receive independently analysed research compounds supported by detailed Certificates of Analysis and transparent batch-specific laboratory documentation. For GLOW 70 mg batch GF-GLOW70-B242, independent analysis was performed by Liquilabs s.r.o. Czechia and the Certificate of Analysis was published on 10 September 2026. All three peptide components were independently evaluated for assay content, purity and identity. The analytical programme additionally included bacterial endotoxin testing, microbiological analysis, elemental impurity screening and molecular ion mass identification. This multi-method analytical approach provides researchers with extensive independent information regarding the individual components within the tested GLOW 70 mg research preparation.  

Research Use Limitation

• Used solely for laboratory and in vitro research
• Not approved for human consumption
• Not approved for veterinary use
• Not intended for diagnostic purposes
• Not intended for therapeutic applications
• Not permitted for clinical administration
• For research use only

• Independently analysed by Liquilabs s.r.o. Czechia
• Contains 50 mg GHK-Cu, 10 mg BPC-157 and 10 mg Thymosin Beta 4 (TB-500)
• Greater than 99.8 % purity confirmed for all three peptide components
• GHK-Cu assay content verified at 49.6 mg
• BPC-157 assay content verified at 8.96 mg
• Thymosin Beta 4 (TB-500) assay content verified at 10.95 mg
• Identity confirmed by spectrum, retention time and mass spectrometry analysis
• Molecular ion masses identified at 340 Da, 1418 Da and 4963 Da
• Bacterial endotoxin level below 0.001 EU/mg
• No detectable heavy metals or microbial contamination
• Multi-peptide research preparation with complete COA traceability
• For research use only – not for human or veterinary use

For laboratory research only. Not intended for human consumption, injection, or cosmetic use.

This product is for research purposes only. Not for human use or diagnostic/therapeutic applications. Keep out of reach of children.